plasma viral load

plasma viral load (PVL),

the plasma level of viral RNA, as determined by various techniques including target amplification assay by reverse transcriptase polymerase chain reaction and branched DNA technology with signal amplification. Because levels of detection vary with method, results of testing by different methods are not comparable.

Serial measurement of HIV viral load is a standard procedure to monitor the course of AIDS. Reported as the number of copies of viral RNA per mL of plasma, assessment of viral load provides important information about the number of lymphoid cells actively infected with HIV. This laboratory procedure has supplanted the CD4 count as an indicator of prognosis for people infected with HIV, in determining when to start antiretroviral therapy, and in measuring the response to therapy. Because the CD4 count is regarded as superior in determining the level of immune compromise and the risk of opportunistic infection, both tests are currently used. The U.S. Department of Health and Human Services advises starting antiretroviral therapy when plasma HIV RNA concentration exceeds 10,000-20,000 copies/mL. The International AIDS Society favors an action level of 30,000 copies/mL. When, as a result of treatment, the number of copies of viral RNA falls below the level that can be detected by standard methods, replication of HIV is considered to have been suppressed. In no case, however, has AIDS been cured, nor has viral proliferation remained arrested after cessation of antiretroviral therapy.

References in periodicals archive ?
Second, Models of acute phase plasma viral load obscure early local dynamics of hiv when the virus forms local, Heterogeneous clusters of infection in the genital mucosa before entering the lymphatic and blood systems.
DURBAN, SOUTH AFRICA -- Long-acting injectable antiretroviral therapy with cabotegravir and rilpivirine in nanosuspension successfully suppressed HIV-infected patients' plasma viral load to fewer than 50 copies /mL for 48 weeks as maintenance therapy in the LATTE-2 trial, David A.
Measuring Plasma Viral Load (PVL) and CD4 counts are crucial for initiating and modifying ART therapy.
However, this over-quantification was observed mainly in specimens with a plasma viral load of <3 000 copies/mL (mean (SD) difference 0.
1% of patients had HIV-1 RNA plasma viral load below the limit of detection (50 copies/mL), and after 12 months this rate increased to 74.
It has been suggested that transmission by someone with an undetectable plasma viral load might be more likely in anal sex.
It is worth noting that these 4 patients were singled out as possible carriers of ciHHV-6 on the basis of HHV-6 plasma viral load levels that were being monitored regularly over time in the context of a research study.
Additional plasma viral load tests performed on blood from the infant over the first three weeks of life again indicated HIV infection.
And if so, would that affect our treatment strategy for these individuals, because primarily, our way of diagnosing and also following an individual is using the plasma viral load or their CD4 count.
4) Precisely, CD4 cell count has been not available, and less often plasma viral load could not be measured.
Although no difference was observed in time to return to ART, or in CD4 counts over time between the Vacc-4x and placebo groups, the data showed a statistically significant treatment difference in plasma viral load set point between the Vacc-4x and placebo groups.
Although no difference was observed in time to return to anti-retroviral therapy (ART), or in CD4 counts over time between the Vacc-4x and placebo groups, the data showed a statistically significant treatment difference in plasma viral load set point between the Vacc-4x and placebo groups.